A reactor system for high throughput applications includes a plurality of reactor assemblies, each reactor assembly including: a fluid source, which fluid source is adapted to provide a pressurized fluid to the flow-through reactors, a flow splitter which flow splitter includes a planar microfluidic chip, which microfluidic chip has a chip inlet channel and a plurality of chip outlet channels, which microfluidic chip further includes a plurality of flow restrictor channels, where each flow restrictor channel extends from said chip inlet channel to an associated chip outlet channel, where the chip inlet channel and the chip outlet channels each have a diameter, where the diameter of the chip inlet channel is the same or less than the length of said chip inlet channel and where the diameter of each chip outlet channel is the same or less than the length of said chip outlet channel.

The present invention provides microfabricated substrates and methods of conducting reactions within these substrates. The reactions occur in plugs transported in the flow of a carrier-fluid.

Provided is a microreactor which can be produced at a lower cost. The microreactor has a transfer means for transferring a liquid raw material using the pressure of a gas. The microreactor has a raw material tank for storing the liquid raw material. The transfer means for transferring a liquid raw material can transfer the liquid raw material stored in the raw material tank using the pressure of a gas in the raw material tank. A pipe which connects the raw material tank and the next device is preferably provided with a small diameter portion.

The present disclosure is directed towards improved systems and methods for large-scale production of nanoparticles used for delivery of therapeutic material. The apparatus can be used to manufacture a wide array of nanoparticles containing therapeutic material including, but not limited to, lipid nanoparticles and polymer nanoparticles. In certain embodiments, continuous flow operation and parallelization of microfluidic mixers contribute to increased nanoparticle production volume.

A photovoltaic apparatus comprising: at least one photovoltaic surface electrically connected to a set of photovoltaic electrodes; and a chemical reactor electrically connected to the set of photovoltaic electrodes. The chemical reactor enables N pairwise fluid contacts among k chemical fluids, with k2 and N4 and comprises: a reaction layer extending in a plane subtended by two directions; N chemical cells, each including two circuit portions, designed for enabling circulation of two of the k chemical fluids, respectively, the two circuit portions intersecting each other, thereby enabling one pairwise fluid contact for the two of the k chemical fluids; and a fluid distribution circuit comprising: k sets of inlet orifices sequentially alternating along lines parallel to one of the two directions; and k sets of outlet orifices sequentially alternating along lines parallel to the inlet orifices, and wherein, each circuit portion connects an inlet orifice to an outlet orifice.

A spatially selective surface functionalization device configured to generate a pattern of micro plasmas and functionalize a substrate surface may include: a pattern management system, a patterning head, and a gas delivery system, wherein the gas delivery system provides a primed gas mixture for forming a plasma between the patterning head and a target substrate below the patterning head. A patterning head may generate a distribution of micro plasmas from individual directed beams of electrons with spatial separation. A pattern management system may store and manipulate information about a pattern of surface functionalization and generate instructions for regulating a distribution of micro plasmas that functionalize a substrate surface.

The disclosed invention relates to a method for restarting a synthesis gas conversion process which has stopped. The synthesis gas conversion process may be conducted in a conventional reactor or a microchannel reactor. The synthesis gas conversion process may comprise a process for converting synthesis gas to methane, methanol or dimethyl ether. The synthesis gas conversion process may be a Fischer-Tropsch process.

According to various embodiments, a method is provided that comprises washing an array of DNA-coated beads on a substrate, with a wash solution to remove stacked beads from the substrate. The wash solution can include inert solid beads in a carrier. The DNA-coated beads can have an average diameter and the solid beads in the wash solution can have an average diameter that is at least twice the diameter of the DNA-coated beads. The washing can form dislodged DNA-coated beads and a monolayer of DNA-coated beads. In some embodiments, first beads for forming an array are contacted with a poly(ethylene glycol) (PEG) solution comprising a PEG having a molecular weight of about 350 Da or less. In some embodiments, slides for forming bead arrays are provided as are systems for imaging the same.

A flow reactor has a module (12) that comprises at least first (20), second (30), and third (40) parallel plates stacked temporarily or permanently together and defining a first thermal fluid layer (25) between the first (20) and second plates (30) and a process fluid layer (35) between the second (30) and third plates (40), the process fluid layer (35) comprising a process fluid passage (32) having two or more U-bends and three or more successive process fluid passage segments joined by respective U-bends, the first thermal fluid layer (25) comprising at least two open thermal fluid channels (26) in the second plate (30), the at least two open channels (26) positioned, when viewed in a plan view of the module (12), between respective adjacent process fluid passage segments.

This disclosure provides systems and methods for the production of formulations of active pharmaceutical ingredients (APIs). In some embodiments, the disclosure provides an automated medicine formulation system comprising a portable and self-contained API formulating apparatus where the API and excipients are formulated to make a drug product meeting drug quality and safety specifications. The automated formulation system produces liquid formulations including, for example, injectable and intravenous medicines. The systems are capable of producing a plurality of individual sterile injectable doses of drug comprising a specific API and excipient(s), which can be formulated on demand in a GMP and FDA acceptable manner.